ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., a leading innovator in women's health, has achieved a significant milestone with the European approval of its FemBloc® System, the first non-surgical permanent birth control solution. The system has received Conformité Européene $(CE)$ mark certification under the European Union Medical Device Regulation, marking the first regulatory approval of its kind globally. The FemBloc System, which includes a blended polymer component and a delivery system, can now be marketed across the European Economic Area. Femasys plans to roll out the product commercially in select European countries, beginning with Spain, while also pursuing further country approvals and continuing U.S. trials for FDA approval.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.